Clinical Trial: Comparing Short to Standard Amoxicillin Course for Erysipelas: a Non-inferiority Randomized Controlled Trial

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07104552) titled 'Comparing Short to Standard Amoxicillin Course for Erysipelas: a Non-inferiority Randomized Controlled Trial' on July 29.

Brief Summary: Erysipela is an acute streptoccocal skin infection (superficial cellulitis), mainly occurring in lower limbs and easily diagnosed. In 2000, the French expert consensus conference validated oral amoxicillin at 3 to 4.5 gr per day for 10 to 20 days, as a standard treatment despite the lack of full market approval in erysipela treatment. Indeed, in current practice, general practitioners (GPs) manage erysipelas by prescribing amoxicillin for around 10 days. In 2019, the Haute Autorite de Sante (HAS), (...